Status:
COMPLETED
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
Lead Sponsor:
Kowa Company, Ltd.
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.
Eligibility Criteria
Inclusion
- Patients show presence of hepatic fat fraction as defined by ≥ 10% on MRI-PDFF at Screening
- Patients show presence of liver stiffness as defined by ≥ 2.5 kPa on MRE at Screening
- Patients have an ALT above the upper limits of normal (30 IU/L for females and 40 IU/L for males) at Screening
- Patients with NAFLD had to be age 20 years or older at written informed consent(ICF)
Exclusion
- Current of significant alcohol consumption (significant alcohol consumption is defined as more than 210 g/week in males and more than 140 g/week in females, on average)
- Planned use of Contraindicated Medications from written ICF to end of treatment.
- BMI \< 22 kg/m2 at Screening
- Uncontrolled diabetes mellitus as defined by a HbA1c(NGSP) ≥ 8.0％ at Screening
- eGFR \< 30 mL/min/1.73m2 or Dialysis patient
- Cirrhosis
- Biliary obstruction
- Patients were excluded if they had evidence of other forms of liver disease shown by the following:
- Hepatitis B or Hepatitis C
- Autoimmune hepatitis（AIH）
- Primary biliary cirrhosis（PBC）
- Primary Sclerosing Cholangitis（PSC）
- Drug-induced liver injury
- hyperthyroidism, Wilson's disease, hemochromatosis, alpha-1-antitrypsin disease
- Those with complicating malignant neoplasm or those judged to be at a high risk of recurrence
- Patients with contraindications to MRI imaging
- Patients who gave 200 mL or more of blood within 1 month before the administration of the study drug, or 400 mL or more of blood within 4 months before the administration of the study drug
- Patients with a history of serious drug allergies (such as anaphylactic shock)
- Pregnancy, breast feeding, planned pregnancy
- Patients who were participating in another clinical study at the time of consent was obtained or who received study drugs other than the placebo less than 16 weeks before consent was obtained
- Patients who have previously been administered pemafibrate
- Patients who have been determined inappropriate by the investigator or subinvestigator
Key Trial Info
Start Date :
December 27 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT03350165
Start Date
December 27 2017
End Date
June 30 2020
Last Update
April 9 2021
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Aomori Prefectural Central Hospital
Aomori, Aomori, Japan, 030-8553
2
Asahikawa Medical University
Asahikawa, Hokkaido, Japan, 078-8510
3
Fukuwa Clinic
Chuo-ku, Tokyo, Japan, 104-0031
4
Fukuoka University Hospital
Fukuoka, Fukuoka, Japan, 814-0180